Jan–Dirk Studt - Concepedia

Author

Jan–Dirk Studt

University Hospital of Zurich

Also Known As

J Studt, J. D. Studt, J.-D. Studt, J.‐D. Studt, Jan-Dirk Studt, Jan‐Dirk Studt, Jan–Dirk Studt, Studt, Jan-Dirk

Publications

4.1K

Citations

H-Index

Concepts

All Affiliations

University Hospital of Zurich University Hospital of Bern University of Bern University of Zurich University Hospital of Basel

About

Jan–Dirk Studt is an author at University Hospital of Zurich specializing in medicine, thrombosis, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	661
2	Natural Sciences	2	2	186
3	Public Health	2	2	160
4	Engineering	1	1	34
5	Health Sciences	1	1	13

Jan–Dirk Studt

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy Corrado Lodigiani, G. Iapichino, Luca Carenzo, Thrombosis Research	2020	2.1K
Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin Jan–Dirk Studt, Johanna A. Kremer Hovinga, Gerhard Antoine, Blood	2004	153
Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation Nina Khanna, I. Steffen, Jan–Dirk Studt, Transplant Infectious Disease	2009	120
<i>ADAMTS13</i> gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor‐cleaving protease activity by recombinant human ADAMTS13 Gerhard Antoine, Klaus F. Zimmermann, Barbara Plaimauer, British Journal of Haematology	2003	102
Thromboprophylaxis and laboratory monitoring for in-hospital patients with Covid-19 - a Swiss consensus statement by the Working Party Hemostasis Alessandro Casini, Lorenzo Alberio, Anne Angelillo‐Scherrer, Swiss Medical Weekly ThrombosisMedicineLaboratory MonitoringHematologyWorking Party Hemostasis	2020	97
Measurement of von Willebrand factor cleaving protease (ADAMTS‐13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas Armando Tripodi, Veena Chantarangkul, Martina Böhm, Journal of Thrombosis and Haemostasis International Collaborative StudyVon Willebrand FactorMedicineNatural SciencesBioanalysis	2004	95
Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods Jan–Dirk Studt, Martina Böhm, Ulrich Budde, Journal of Thrombosis and Haemostasis Proteomic TechnologyBiochemistryMedicineNatural SciencesBioanalysis	2003	91
Von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience Johanna A. Kremer Hovinga, Jan–Dirk Studt, Lorenzo Alberio, Seminars in Hematology ThrombopoiesisThrombosisVenous ThrombosisActivity DeterminationImmunology	2004	79
COVID‐19 patients often show high‐titer non‐platelet‐activating anti‐PF4/heparin IgG antibodies Justine Brodard, Johanna A. Kremer Hovinga, Pierre Fontana, Journal of Thrombosis and Haemostasis	2021	73
Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. Johanna A. Kremer Hovinga, Jan–Dirk Studt, Franziska Demarmels Biasiutti, PubMed	2004	66

Page 1